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Abstract
Background: The insertion/deletion (I/D) polymorphism in the Angiotensin-converting enzyme (ACE) gene has been
implicated in susceptibility to cancer, but a large number of studies have reported inconclusive results. The aim of
this study is to assess the association between the I/D polymorphism in the ACE gene and cancer risk by meta-
analysis.
Methods: A search was performed in Pubmed database, Embase database, Chinese Biomedical (CBM) database,
China National Knowledge Infrastructure (CNKI) database and Weipu database, covering all studies until August 31,
2010. Statistical analysis was performed by using Revman4.2 and STATA 10.0.
Results: A total of 25 case-control studies comprising 3914 cancer patients and 11391 controls were identified. No
significant association was found between the I/D polymorphism and over all cancer risks (OR = 0.88, 95%CI =
0.73-1.06, P = 0.17 for DD+DI vs. II). In the subgroup analysis by ethnicity, no significant association was found
among Asians and Europeans for the comparison of DD+DI vs. II. In the subgroup analysis by cancer types, no
significant associations were found among lung cancer, breast cancer, prostate cancer, colorectal cancer, gastric
cancer for the comparison of DD+DI vs. II. Results from other comparative genetic models also indicated the lack
of associations between this polymorphism and cancer risks.
Conclusions: This meta-analysis suggested that the ACE D/I polymorphism might not contribute to the risk of
cancer.
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Background
The angiotensin-converting enzyme (ACE), a key
enzyme in the renin-angiotensin system, plays the
important roles of regulating of blood pressure and
serum electrolytes [1,2]. It has also been implicated in
the pathogenesis of several cancers, such as lung cancer,
breast cancer, prostate cancer, gastric cancer and oral
cancer [2-6]. It is differentially expressed in several car-
cinomas and may affect tumor cell proliferation, migra-
tion, angiogenesis, and metastatic behaviors [7].
Inhibition of ACE activity suppresses tumor growth and
angiogenesis in vitro and vivo of animal models; more-
over, epidemiologic studies have also indicated that ACE
inhibitors might decrease the risk and mortality rate of
cancers [2,7].
The human ACE gene is located on chromosome
17q23, and many polymorphisms have been identified
[8]. The most widely studied polymorphism Insertion/
Deletion (I/D, rs4646994) is located on intron 16[6]. It
is characterized by the presence or absence of a 287-bp
Alu repetitive sequence, which results in three geno-
types: II, DI and DD [6]. The I/D polymorphism
accounts for 20% to 50% of the variance in ACE expres-
sion or activity in blood and tissues among individuals
[7]. Homozygote II may display as low as half of the
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whereas the heterozygote DI displays an intermediate
level[2]. Recently, many studies investigated the role of
this polymorphism in the etiology of cancers among var-
ious organs, including lung, breast, prostate, gastric, oral
and others [3-7,9-18]. However, the observed associa-
tions of these studies were inconsistent, and a single
study might be insufficient to detect a possible small
effect of the polymorphism on cancers. Meta-analysis is
a useful method for investigating the associations
between diseases and risk factors because it uses a quan-
titative approach to combine the results of different stu-
dies on the same topic, potentially providing more
reliable conclusions [19,20]. Considering the extensive
role of ACE in the pathogenesis of cancers, a meta-ana-
lysis was performed on all eligible case-control studies
to estimate the association between this polymorphism
and cancer risks.
Methods
Publication search
We searched literatures in Pubmed database, Embase
database, Chinese Biomedical database(CBM) database,
Chinese National Knowledge Infrastructure(CNKI) data-
base and Weipu database to identify articles that evalu-
ated the associations between polymorphisms in ACE
gene and cancer risks(Last search was updated on Aug
31st, 2010). The search terms were used as follows: ‘can-
cer or carcinoma’ and ‘ACE or angiotensin-converting
enzyme’ in combination with ‘polymorphism or mutation
or variant’. The languages were limited to English and
Chinese. The following inclusion criteria were used in
the meta-analysis: (1) the study should evaluate the I/D
polymorphism in ACE gene and cancer risk, (2) the
study should be a case-control design, (3) enough infor-
mation had to be provided to calculate the odds ratio
(OR) with 95% confidence interval (CI), (4) the distribu-
tion of genotypes in the control groups should be con-
sistent with Hardy-Weinberg equilibrium (HWE).
Accordingly, the following exclusion criteria were also
used: (1) abstracts and reviews, (2) studies in which the
genotype frequencies were not reported, (3) repeated or
overlapped publications. For studies with the same case
series by the same authors, the most recently published
studies or studies with the largest numbers of subjects
were included.
Data extraction
Data were independently checked and extracted by two
investigators. The following items were collected from
each study: first author’s name, year of publication,
country of origin, ethnicity, genotyping methods, cancer
type, total number of cases and controls, genotype dis-
tributions in cases and controls.
Statistical analysis
For each case-control study, the HWE of genotypes in
the control group was assessed by using Person’s X
2
test. OR and 95% CI was used to assess the strength of
the association between the I/D polymorphism and can-
cer risk. We calculated the OR and respective 95% CI
by comparing the carriers of rare alleles with the wild
homozygotes (DI+DD vs. II).
Heterogeneity among studies was assessed by a X
2
based Q- and I
2- statistic. Heterogeneity was considered
significant for P less than 0.10. The fixed-effects model
and random-effects model were used to pool the results.
When the P value of heterogeneity was greater than
0.10, the fixed-effects model was used, otherwise, the
random-effects model was used, as it is more appropri-
ate when heterogeneity is present. The significance of
the pooled OR was determined by the Z-test and P less
than 0.05 was considered as statistically significant. To
evaluate the ethnicity-specific, cancer type-specific
effects, subgroup analyses were performed by ethnic
group (’European’, ‘Asian’, ‘African-American’ and
‘Latino’) and cancer types. Subgroup analyses by ethni-
city were preformed if one ethnic population included
more than three case-control studies. Subgroup analysis
by cancer type were preformed if one cancer type can-
teined three and more than three individual studies.
Comparisons of other genetic models were also per-
formed (DD vs. DI+II, DD vs. II, DI vs. II and D vs. I).
Publication bias was investigated by using several
methods. Visual inspection of asymmetry in funnel plots
was carried out. The Begg’s funnel plots and Egger’st e s t
were also used to statistically assess publication bias
[21,22]. Sensitivity analysis was performed to assess the
stability of the results by sequentially excluding each
study [23]. All analyses were performed using the soft-
ware Revman4.2 and STATA 10.0.
Results
Studies selection and characteristics in the meta-analysis
There were 486 results relevant to the search words in
the selected databases (Figure 1). After reading the titles
and abstracts, 39 potential articles were included for
full-text view. Further screening of these articles, three
of them were excluded for being not relevant to cancer
risk with ACE gene polymorphism. Thus, 36 articles
were left for data extraction. Six articles were excluded
for not reporting the usable data. One article reported
four cohorts each and each cohort was considered as a
separate case-control study [6]. Thus, a total of 33 case-
control studies in 30 articles were identified. Addition-
ally, 5 case-control studies were excluded for the geno-
types in control group not consistent with HWE[24-28],
and 3 case-control studies were excluded for data over-
lapped or duplicated. Thus, a total of 25 case-control
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[3-7,9-13,15-18,29-33,14,34,35]. The characteristics of
included case-control studies are summarized in Table
1. Genotype and allele distributions for each case-con-
trol study are shown in Table 2. There were 8 studies of
Asians [4,6,10,11,14,29,30,33], 14 of Europeans
[3,5-7,9,12,13,15-17,31,32,34,35], 2 of Latinos [6,18], 1 of
African-Americans [6]. In this meta-analysis, the most
studied cancers were lung cancer and breast cancer, the
genotype methods are a classic PCR assays
Meta-analysis results
As shown in Figure 2, heterogeneity of DD+DI vs. II for all
studies was analyzed and the value of X
2 was 79.09 with 24
degrees of freedom and P < 0.00001 in a random-effects
model. Additionally, I-square value is another index of the
test of heterogeneity. In Figure 2, the I-square was 69.7%,
suggesting the presence of heterogeneity. Thus, the ran-
dom-effects model was chosen to synthesize the data. OR
was 0.88(95%CI = 0.73-1.06) and the test for overall effect
Z value was 1.38 (P = 0.17). The results suggested that the
variant D allele carriers (DI+DD) do not have a significant
increased risk of cancer compared with those individuals
without D allele (II). Summary of the results of other
genetic comparisons are listed in Table 3.
Subgroup analyses were performed after stratifications
of the data by ethnicity and cancer types. In the sub-
group analysis by ethnicity (Figure 3), no significant
increased risks were found in Europeans and Asians.I n
the subgroup analysis by cancer types (Figure 4), no sig-
nificant increased risk was found in lung cancer, breast
cancer, colorectal cancer, gastric cancer, prostate cancer.
Figure 1 Flow diagram of included/excluded studies.
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different population and different cancers.
Publication bias
Begg’s funnel plot and Egger’s test were performed to
assess the publication bias of the literatures. The shape
of the funnel plots seemed approximately symmetrical
(DD+DI vs. II) and the Egger’st e s td i dn o ts h o wa n y
evidence of publication bias (t =0 . 4 5a n dP = 0.655 for
DD+DI vs. II) (Figure 5).
Sensitivity analysis
Sensitivity analysis was analyzed as previous study [23].
Briefly, after excluding each case-control study for DD
+DI vs. II comparative (Table 4), statistically similar
results were obtained, suggesting the results of this
meta-analysis are stable.
Discussion
ACE is a key enzyme in the renin-angiotensin system,
which is involved in the regulation of blood pressure
and serum electrolytes. In recent years, more evidences
indicated that the enzyme was associated with the
pathogenesis of cancers. It may influence tumor cell
proliferation, migration, angiogenesis and metastatic
behaviors. Given the important roles of ACE in cancer
etiology, it is possible that genetic variations of the ACE
gene may modulate the risk of cancer. The I/D poly-
morphism in intron 16 of the ACE gene is the most
extensively studied polymorphism. This polymorphism
is based on insertion or deletion of a 287-bp Alu
sequence, leading to a change in the plasma ACE level.
Growing number of studies have been published to
investigate the associations between this polymorphism
with cancer risk; however, the results were inconsistent
and conflict. In order to resolve this issue, we conducted
a meta-analysis of 25 case-control studies, including
3914 cases and 11391 controls, to evaluate the associa-
tions between the ACE I/D polymorphism and cancer
risks.
Our results showed that the ACE I/D polymorphism
was not associated with cancer risks. Moreover, in other
comparative genetic models, no significant associations
w e r ef o u n di na n yg e n e t i cm o d e l s .T h e s er e s u l t si n d i -
cated that this polymorphism may not contribute to
cancer risks. Although previous studies revealed possible
Table 1 Characteristics of case-control studies included in meta-analysis
Author Year Country Ethnicity Cancer type No.(Cases/Controls) Genotyping
method
Arima, H[14] 2006 Japan Asian Cancers 176/761 PCR
Bardi, E[34] 2005 Hungary European Cancers 207/144 PCR
Cheon, K T[29] 2000 Korea Asian Lung 218/121 PCR
Ding, × J[30] 2008 China Asian Lung 121/33 PCR
Goto, Y[10] 2005 Japan Asian Gastric 202/454 PCR
Haiman, C A(AF)[6] 2003 USA African-American Breast 257/631 PCR
Haiman, C A(JP)[6] 2003 USA Asian Breast 284/357 PCR
Haiman, C A(Latinas)[6] 2003 USA Latino Breast 249/652 PCR
Haiman, C A(Whites)[6] 2003 USA European Breast 292/402 PCR
Holla, L[35] 1998 Czech European Leukemia 25/202 PCR
Nacak, M[3] 2010 Turkey European Lung 125/165 PCR
Nikiteas, N[16] 2007 Greece European colorectal 92/102 PCR
Rocken, C[7] 2005 Germany European Gastric 113/189 PCR
Rocken, C[31] 2007 Germany European Colorectal 141/189 PCR
Sierra, Diaz E[18] 2009 Mexico Latino Prostate 19/28 PCR
Sugimoto, M[4] 2006 Japan Asian Gastric 119/132 PCR
Toma, M[13] 2009 Romanian European Colorectal 108/150 PCR
Tunny, T J[17] 1996 Australia European Aldosterone-producing
adenoma
55/80 PCR
Vairaktaris, E[32] 2009 Greece European Oral 160/153 PCR
van der Knaap, R[12] 2008 Netherlands European Colorectal, lung,
breast, prostate
655/6015 PCR
Vaskù, V[9] 2004 Czech European T-cell lymphoma 77/203 PCR
Wang, H W[11] 2000 China Asian Lung 34/38 PCR
Yeren, A[15] 2008 Turkey European Lung 75/85 PCR
Yigit, B[5] 2007 Turkey European Prostate 48/51 PCR
Zhang Q Z[33] 2005 China Asian Lung 47/54 PCR
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that these roles may not account by the variant of ACE
gene. Although the exact mechanism of this enzyme in
cancer etiology is not so clear, our results may indicate
that ACE I/D polymorphism may not influence cancer
risk. In addition, considering the possible role of this
polymorphism in serum ACE level, it is possible that
the cancer risk may be modified by ACE level, but not
by the variant. Thus, future studies are warranted to
identify the associations between ACE polymorphism,
ACE levels and cancer risk.
Considering the property of genetic background may
affect the results of genetic association studies, we per-
formed subgroup analysis by ethnicity. Two subgroups
were included in this meta-analysis: ‘European’ and
‘Asian’. In this meta-analysis, we didn’t find a significant
association between this polymorphism and cancer risk
in any sub-populations. Moreover, no significant asso-
ciations were found in any other genetic models. Inter-
estingly, this polymorphism and cancer risk in Asians
and Europeans were all inversely associated, although
they were not statistically significant. These results may
suggest that this polymorphism may exert varying
effects in different populations. However, all included
studies were from European, Asian, African-American
and Latino populations, further studies are necessary to
validate these findings for other ethnic populations,
especially in Africans.
In another subgroup analysis by cancer types, we
found that this polymorphism is not associated with
increased risks in all sub-cancer types (lung, breast,
prostate, gastric and colorectal). Considering the limita-
tion of studies in each subgroup, the weak associations
between this polymorphism and different cancers should
be discussed. It is possible that these null associations
may be due to chance because studies with small sample
size may have insufficient statistical power to detect a
slight effect. Considering the limited studies in each
cancer type, our results should be explained with
caution.
Heterogeneity is one of the important issues when
performing meta-analysis. We found that heterogeneity
between studies existed in overall comparisons. After
subgroup analysis by ethnicity and cancer types, the het-
erogeneity was effectively decreased or removed in
Asians and some cancer types, suggesting that certain
effects of genetic variants are cancer specific and ethnic
specific. The stability of this meta-analysis was analyzed
Table 2 Distribution of ACE genotype and allele among asthma patients and controls
Author Case Control Case Control HWE for control population
II ID DD II DI DD I D I D X2 P
Arima, H[14] 65 87 24 295 372 94 217 135 962 560 1.978 0.160
Bardi, E[34] 74 89 44 52 71 21 237 177 175 113 0.166 0.683
Cheon, K T[29] 72 116 30 48 50 23 260 176 146 96 2.261 0.132
Ding, × J[30] 55 56 10 19 10 4 166 76 48 18 1.840 0.175
Goto, Y[10] 76 98 28 209 189 56 250 154 607 301 1.674 0.196
Haiman, C A(AF)[6] 62 118 77 100 310 221 242 272 510 752 0.254 0.614
Haiman, C A(JP)[6] 119 128 37 154 160 43 366 202 468 246 0.021 0.884
Haiman, C A(Latinas)[6] 73 127 49 189 301 162 273 225 679 625 3.677 0.055
Haiman, C A(Whites)[6] 79 129 84 91 187 124 287 297 369 435 1.613 0.204
Holla, L[35] 25 11 4 40 86 76 61 19 166 238 2.937 0.087
Nacak, M[3] 37 50 38 29 72 64 124 126 130 200 1.225 0.268
Nikiteas, N[16] 15 50 27 6 52 44 80 104 64 140 3.451 0.063
Rocken, C[7] 24 57 32 41 95 53 105 121 177 201 0.017 0.898
Rocken, C[31] 37 69 35 41 95 53 143 139 177 201 0.017 0.898
Sierra, Diaz E[18] 0 7 12 9 12 7 7 31 30 26 0.537 0.464
Sugimoto, M[4] 54 53 12 50 60 22 161 77 160 104 0.305 0.581
Toma, M[13] 25 50 33 30 73 47 100 116 133 167 0.029 0.864
Tunny, T J[17] 16 25 14 24 34 22 57 53 82 78 1.787 0.181
Vairaktaris, E[32] 30 70 60 9 66 78 130 190 84 222 1.054 0.305
van der Knaap, R[12] 141 329 185 1332 3006 1677 611 699 5670 6360 0.047 0.828
Vaskù, V[9] 19 37 21 43 103 57 75 79 189 217 0.078 0.780
Wang, H W[11] 10 6 18 13 18 7 26 42 44 32 0.031 0.861
Yeren, A[15] 4 39 32 14 37 34 47 103 65 105 0.522 0.470
Yigit, B[5] 4 19 25 12 24 15 27 69 48 54 0.157 0.692
Zhang Q Z[33] 21 21 5 20 30 4 63 31 70 38 2.567 0.109
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indicated stability of results. Publication bias is another
important issue which should also be discussed in meta-
analysis. After evaluating the publication bias by Egger’s
funnel plots and Begg’s test, we did not detect a publica-
tion bias, indicating the strength of the results.
Cancers have been considered as genetic diseases, and
many genetic variants are contributed to cancer risks
[36-40]. It is worthy to mention the recently studies of
genetic analysis by genome wide-association studies
(GWAS). Up to now, a large number of GWAS for cancers
have been published, and a large number of cancer suscep-
tible loci were found [36-38,41-46]. However, none of them
indicated the ACE D/I polymorphism, which can be partly
explained by the chips which were used in the original stu-
dies. There is probably a lack of adequate coverage on
Figure 2 Meta-analysis with a random-effects model for the association between cancer risk and the ACE I/D polymorphism (DD+DI
vs II).
Table 3 Summary of different comparative results
Variables N Cases/Controls DD+DI vs II DD vs DI+II DD vs II D vs I DI vs II
OR(95%CI) P* OR(95%CI) P* OR(95%CI) P* OR(95%CI) P* OR(95%CI) P*
Total 25 3914/11391 0.88(0.73, 1.06) 0.38 0.93(0.80, 1.09) 0.39 0.90(0.73, 1.12) 0.34 0.94(0.83, 1.07) 0.34 0.89(0.75, 1.06) 0.20
Subgroup by
ethnicity
Asian 8 1201/1950 1.13(0.96, 1.33) 0.15 1.05(0.74, 1.49) 0.78 1.09(0.83, 1.44) 0.53 1.08(0.93, 1.25) 0.34 0.85(0.68, 1.06) 0.14
European 14 2188/8130 0.89(0.73, 1.09) 0.26 0.89(0.73, 1.09) 0.26 0.76(0.53, 1.08) 0.12 0.86(0.71, 1.03) 0.10 0.78(0.60, 1.01) 0.06
Subgroup by cancer
type
Lung 7 737/6511 1.04(0.70, 1.55) 0.85 0.99(0.67, 1.48) 0.98 1.02(0.62, 1.69) 0.93 1.03(0.80, 1.31) 0.83 1.01(0.64, 1.61) 0.95
Breast 5 1235/8057 0.88(0.71, 1.09) 0.24 0.95(0.75, 1.21) 0.70 0.86(0.64, 1.16) 0.33 0.94(0.81, 1.09) 0.41 0.88(0.72, 1.09) 0.24
Colorectal 4 517/6456 0.81(0.53, 1.24) 0.34 0.83(0.66, 1.05) 0.11 0.73(0.45, 1.18) 0.20 0.87(0.71, 1.06) 0.17 0.87(0.58, 1.31) 0.50
Gastric 3 434/775 1.06(0.71, 1.59) 0.78 0.94(0.66, 1.36) 0.76 0.96(0.55, 1.65) 0.87 1.00(0.74, 1.34) 1.00 1.12(0.79, 1.58) 0.52
Prostate 3 276/6094 2.44(0.66, 8.97) 0.18 2.05(0.74, 5.62) 0.17 3.48(0.63, 19.13) 0.15 2.05(0.84, 5.02) 0.11 1.66(0.67, 4.07) 0.27
*: P value for Q-test.
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Page 6 of 10Figure 3 Meta-analysis with a random-effects model for the association between cancer risk and the ACE I/D polymorphism (DD+DI
vs II): subgroup analysis by ethnicity.
Figure 4 Meta-analysis with a random-effects model for the association between cancer risk and the ACE I/D polymorphism (DD+DI
vs II): subgroup analysis by cancer type.
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s e q u e n c e .I ti sn o t e dw o r t h y ,t h eS N Pr s 4 3 4 3 ,w h i c hi sc o n -
sidered as a good proxy in Caucasians for I/D variant (r2 >
0.80), have been studied by Illumina genotyping arrays
[47,48]. Thus, further studies may investigate rs4343 for
cancer risk by GWAS to help to resolve whether the I/D
polymorphism is associated with cancer risk.
We have to mention a recently published study by Ruiter
in 2011[49]. They also investigated the ACE I/D poly-
morphism with the risk of cancers. There were some differ-
ences between these two studies. First, the current meta-
analysis included more case-control studies than Ruiter’s
study. Second, some issues which may affect the results of
meta-analysis were addressed in our study, such as publica-
tion bias, sensitivity analysis and HWE analysis. Third, the
current study is a meta-analysis, and Ruiter’s study is more
like a review. Despite of these differences, our study also
indicated the ACE I/D polymorphism might not contribute
to the risk of cancer, which is consistent with Ruiter’ss t u d y .
Some limitations of this study should be addressed. First,
only published studies in Chinese and English which were
included by the selected databases were included for data
analysis, some potential studies which were included by
other databases or published with other languages or
unpublished could be missed. Second, due to lack of origi-
nal data, we could not evaluate the potential interactions of
gene-gene and gene-environment. Third, this meta-analysis
included data from Europeans, Asians, African-American
and Latino populations, so that, the results are applicable
to only these ethnic groups. Fourth, it is reported that PCR
amplification of ACE I/D polymorphism using only flank-
ing primer pairs would misclassify 4-5% of the ID genotype
as the DD genotype and a second PCR should performed
to confirm the DD genotype[50]. However, only a small
portion of included studies performed a second PCR, indi-
cating the possibility of imprecise results of the meta-analy-
sis. Fifth, some other important factors may also bias our
results, such as smoking status, the heterogeneity of cancer
patients (pre- or post -menopausal breast cancer patients);
genotyping technique changes over time and other
unknown function of RAS system et al. However, this
meta-analysis also has some advantages. First, the compre-
hensive meta-analysis included more than 15,000 indivi-
duals; it is statistically more powerful than any single study.
Figure 5 Begg’s funnel plot for publication bias in selection of studies on the ACE I/D polymorphism (DD+DI vs II).
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cancer risk and ACE D/I polymorphism and the result also
indicated a gene in RAS may not contribute to cancer risk.
Third, the result of publication bias is not significant; indi-
cating the conclusion of this study may be unbiased.
In summary, this meta-analysis suggests that the I/D
polymorphism in the ACE gene may not contribute to sus-
ceptibility to cancer. However, larger well-designed studies
are warranted to validate these findings. Moreover, future
studies should also investigate gene-gene and gene-envir-
onment interactions to better display the association
between the polymorphisms in ACE gene and cancer risk.
Conclusion
These results suggest that the D/I polymorphism in
ACE gene may not contribute to susceptibility to cancer.
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